Download - HIV Vaccine
![Page 1: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/1.jpg)
60 million people, infected since 198139.5 million people are living with HIV 4.3 million new infections in 2006 Over 28 million have died since 1981 Ten new infections occur every minute
![Page 2: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/2.jpg)
![Page 3: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/3.jpg)
![Page 4: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/4.jpg)
FactsSpecial Features of HIVHuman Immune System ResponseIdeal HIV VaccineCurrent AchievementsProspective
![Page 5: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/5.jpg)
FactsFacts
AIDS kills more people than any other infectious disease Impact on economics Unreliable pharmacotherapy HIV is the best studied pathogen Yet we don’t have any vaccine for it
![Page 6: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/6.jpg)
FactsSpecial Features of HIVHuman Immune System ResponseIdeal HIV VaccineCurrent AchievementsProspective
![Page 7: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/7.jpg)
Special Features of HIV
HIV is highly mutable Genetically diverse
population of viruses Too variable epitopes
of the viral envelope Masking of gp120 High levels of viral replication Long latent period of infection
![Page 8: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/8.jpg)
![Page 9: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/9.jpg)
Special Features of HIV
GP 120
![Page 10: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/10.jpg)
Slide 7.37
![Page 11: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/11.jpg)
FactsSpecial Features of HIVHuman Immune System ResponseCurrent AchievementsAn Ideal HIV VaccineProspective
![Page 12: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/12.jpg)
Human Immune System Response
Humeral immunity
![Page 13: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/13.jpg)
Human Immune System Response
Cell-mediated immunity
![Page 14: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/14.jpg)
FactsSpecial Features of HIVHuman Immune System ResponseCurrent AchievementsAn Ideal HIV VaccineProspective
![Page 15: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/15.jpg)
Current Achievements
Since 2000
30 vaccine versions have been tried Many clinical trials are ongoing in
developing countries Large scale AIDS vaccine
trials could be conducted
![Page 16: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/16.jpg)
Current Achievements
![Page 17: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/17.jpg)
Live Attenuated
Whole Killed
Live Vector
Re-combinant Proteins
DNA Vaccines
Pseudovirion
Vaccine Types
Current Achievements
![Page 18: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/18.jpg)
Whole, Killed HIV
Not under study in primates
No useful immunity
Difficult to maintain viral configuration
Difficult to make large quantities
![Page 19: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/19.jpg)
Live, Attenuated HIV
Studied in non-human primates
Has pathogenic potentiality
![Page 20: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/20.jpg)
Live Vector Vaccines
Phase I and II trials
Inserting HIV or SIV genes into viruses or bacteria
Effective humoral and cellular immune responses
![Page 21: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/21.jpg)
Recombinant Viral Protein Vaccines
Phase III
Uses viral surface
antigens as
immunogens
Uses genetically
engineered bacteria,
yeasts, insects or cell
cultures
![Page 22: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/22.jpg)
Naked DNA Vaccines
Stages I , I/II and II
Synthesizing antigens using
host-cell’s machinery
Presented on the cell
surface with host MHC class
I and class II molecules
![Page 23: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/23.jpg)
Pseudovirions
Pre-clinical trialsVirus-like particlesSelf-assembling,
non- replicating, virus-sized structures
![Page 24: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/24.jpg)
FactsSpecial Features of HIVHuman Immune System ResponseCurrent AchievementsAn Ideal HIV VaccineProspective
![Page 25: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/25.jpg)
An Ideal HIV VaccineAn Ideal HIV Vaccine
SterilizingLong-term controlled infection
Transient Infection
Altruistic vaccine
![Page 26: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/26.jpg)
Epidemiological Aspect
Individual Aspect
An Ideal HIV VaccineAn Ideal HIV Vaccine
![Page 27: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/27.jpg)
Efficacy
Protection from infection
Sterilizing immunity Protection from
disease
Reduction in set point viral loads
Time after infection
Vir
al lo
adIdeal vaccine
Peak
Set point
Sub optimal vaccine
![Page 28: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/28.jpg)
FactsSpecial Features of HIVHuman Immune System ResponseCurrent StandAn Ideal HIV VaccineProspective
![Page 29: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/29.jpg)
Total New Infections Averted By An AIDS VaccineN
ew in
fect
ions
in m
illi
on
Vaccine introduction
Base
Low scenario
Medium scenario
High scenario
Total new infections averted by an AIDS vaccine between 2015-2030
30% efficacy
20% coverage
50% efficacy
30% coverage
70% efficacy
40% coverage
5.5 million
28 million
17 million
28 million
![Page 30: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/30.jpg)
Is an AIDS vaccine really Preparable?
Is an AIDS vaccine really Preparable?
In 1984 researchers predicted that a
vaccine was right around the corner…
![Page 31: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/31.jpg)
INTERNATIONAL HEALTH SECURITY 2007
…..HIV/AIDS threatens the stability of entire
regions and nations…. While there are major
efforts under way to find
a vaccine and to expand access to
affordable treatments, much more still needs to
be done…
![Page 32: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/32.jpg)
What To Do Now?
![Page 33: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/33.jpg)
Conclusions The scale of HIV problem is huge Humanity needs an effective vaccine to end the
pandemic Developing an HIV vaccine is a laborious task HIV vaccines on different stages of trials are
only partially effective The best primary prevention up till now is :
- Health education
- Personal protection
![Page 34: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/34.jpg)
Acknowledgments
Dr. Seyed Mohsen Mahmoodi Dr. Abdel Hamid Elhawary Mr. Mohammad Reza Rahimi Dr. Rizwana Sheikh
![Page 35: HIV Vaccine](https://reader035.vdocuments.site/reader035/viewer/2022081413/548b08aeb479597f478b4eaf/html5/thumbnails/35.jpg)
THANK THANK YOU!!!YOU!!!
You Can Visit My Website: www.mahmoodi.org